How many etiological subtypes of breast cancer: Two, three, four, or more?

William F. Anderson, Philip S. Rosenberg, Aleix Prat, Charles M. Perou, Mark E. Sherman

Research output: Contribution to journalReview article

92 Citations (Scopus)

Abstract

Breast cancer is a heterogeneous disease, divisible into a variable number of clinical subtypes. A fundamental question is how many etiological classes underlie the clinical spectrum of breast cancer? An etiological subtype reflects a grouping with a common set of causes, whereas a clinical subtype represents a grouping with similar prognosis and/or prediction. Herein, we review the evidence for breast cancer etiological heterogeneity. We then evaluate the etiological evidence with mRNA profiling data. A bimodal age distribution at diagnosis with peak frequencies near ages 50 and 70 years is a fundamental characteristic of breast cancer for important tumor features, clinical characteristics, risk factor profiles, and molecular subtypes. The bimodal peak frequencies at diagnosis divide breast cancer overall into a "mixture" of two main components in varying proportions in different cancer populations. The first breast cancer tends to arise early in life with modal age-atdiagnosis near 50 years and generally behaves aggressively. The second breast cancer occurs later in life with modal age near 70 years and usually portends a more indolent clinical course. These epidemiological and molecular data are consistent with a two-component mixture model and compatible with a hierarchal view of breast cancers arising from two main cell types of origin. Notwithstanding the potential added value of more detailed categorizations for personalized breast cancer treatment, we suggest that the development of better criteria to identify the two proposed etiologic classes would advance breast cancer research and prevention.

Original languageEnglish (US)
Article numberdju165
JournalJournal of the National Cancer Institute
Volume106
Issue number8
DOIs
StatePublished - Aug 1 2014

Fingerprint

Breast Neoplasms
Second Primary Neoplasms
Age Distribution
Neoplasms
Messenger RNA
Research
Population

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cancer Research

Cite this

How many etiological subtypes of breast cancer : Two, three, four, or more? / Anderson, William F.; Rosenberg, Philip S.; Prat, Aleix; Perou, Charles M.; Sherman, Mark E.

In: Journal of the National Cancer Institute, Vol. 106, No. 8, dju165, 01.08.2014.

Research output: Contribution to journalReview article

Anderson, William F. ; Rosenberg, Philip S. ; Prat, Aleix ; Perou, Charles M. ; Sherman, Mark E. / How many etiological subtypes of breast cancer : Two, three, four, or more?. In: Journal of the National Cancer Institute. 2014 ; Vol. 106, No. 8.
@article{6e41efe6ba344d039ab1c12dce9a503f,
title = "How many etiological subtypes of breast cancer: Two, three, four, or more?",
abstract = "Breast cancer is a heterogeneous disease, divisible into a variable number of clinical subtypes. A fundamental question is how many etiological classes underlie the clinical spectrum of breast cancer? An etiological subtype reflects a grouping with a common set of causes, whereas a clinical subtype represents a grouping with similar prognosis and/or prediction. Herein, we review the evidence for breast cancer etiological heterogeneity. We then evaluate the etiological evidence with mRNA profiling data. A bimodal age distribution at diagnosis with peak frequencies near ages 50 and 70 years is a fundamental characteristic of breast cancer for important tumor features, clinical characteristics, risk factor profiles, and molecular subtypes. The bimodal peak frequencies at diagnosis divide breast cancer overall into a {"}mixture{"} of two main components in varying proportions in different cancer populations. The first breast cancer tends to arise early in life with modal age-atdiagnosis near 50 years and generally behaves aggressively. The second breast cancer occurs later in life with modal age near 70 years and usually portends a more indolent clinical course. These epidemiological and molecular data are consistent with a two-component mixture model and compatible with a hierarchal view of breast cancers arising from two main cell types of origin. Notwithstanding the potential added value of more detailed categorizations for personalized breast cancer treatment, we suggest that the development of better criteria to identify the two proposed etiologic classes would advance breast cancer research and prevention.",
author = "Anderson, {William F.} and Rosenberg, {Philip S.} and Aleix Prat and Perou, {Charles M.} and Sherman, {Mark E.}",
year = "2014",
month = "8",
day = "1",
doi = "10.1093/jnci/dju165",
language = "English (US)",
volume = "106",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - How many etiological subtypes of breast cancer

T2 - Two, three, four, or more?

AU - Anderson, William F.

AU - Rosenberg, Philip S.

AU - Prat, Aleix

AU - Perou, Charles M.

AU - Sherman, Mark E.

PY - 2014/8/1

Y1 - 2014/8/1

N2 - Breast cancer is a heterogeneous disease, divisible into a variable number of clinical subtypes. A fundamental question is how many etiological classes underlie the clinical spectrum of breast cancer? An etiological subtype reflects a grouping with a common set of causes, whereas a clinical subtype represents a grouping with similar prognosis and/or prediction. Herein, we review the evidence for breast cancer etiological heterogeneity. We then evaluate the etiological evidence with mRNA profiling data. A bimodal age distribution at diagnosis with peak frequencies near ages 50 and 70 years is a fundamental characteristic of breast cancer for important tumor features, clinical characteristics, risk factor profiles, and molecular subtypes. The bimodal peak frequencies at diagnosis divide breast cancer overall into a "mixture" of two main components in varying proportions in different cancer populations. The first breast cancer tends to arise early in life with modal age-atdiagnosis near 50 years and generally behaves aggressively. The second breast cancer occurs later in life with modal age near 70 years and usually portends a more indolent clinical course. These epidemiological and molecular data are consistent with a two-component mixture model and compatible with a hierarchal view of breast cancers arising from two main cell types of origin. Notwithstanding the potential added value of more detailed categorizations for personalized breast cancer treatment, we suggest that the development of better criteria to identify the two proposed etiologic classes would advance breast cancer research and prevention.

AB - Breast cancer is a heterogeneous disease, divisible into a variable number of clinical subtypes. A fundamental question is how many etiological classes underlie the clinical spectrum of breast cancer? An etiological subtype reflects a grouping with a common set of causes, whereas a clinical subtype represents a grouping with similar prognosis and/or prediction. Herein, we review the evidence for breast cancer etiological heterogeneity. We then evaluate the etiological evidence with mRNA profiling data. A bimodal age distribution at diagnosis with peak frequencies near ages 50 and 70 years is a fundamental characteristic of breast cancer for important tumor features, clinical characteristics, risk factor profiles, and molecular subtypes. The bimodal peak frequencies at diagnosis divide breast cancer overall into a "mixture" of two main components in varying proportions in different cancer populations. The first breast cancer tends to arise early in life with modal age-atdiagnosis near 50 years and generally behaves aggressively. The second breast cancer occurs later in life with modal age near 70 years and usually portends a more indolent clinical course. These epidemiological and molecular data are consistent with a two-component mixture model and compatible with a hierarchal view of breast cancers arising from two main cell types of origin. Notwithstanding the potential added value of more detailed categorizations for personalized breast cancer treatment, we suggest that the development of better criteria to identify the two proposed etiologic classes would advance breast cancer research and prevention.

UR - http://www.scopus.com/inward/record.url?scp=84906996719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906996719&partnerID=8YFLogxK

U2 - 10.1093/jnci/dju165

DO - 10.1093/jnci/dju165

M3 - Review article

C2 - 25118203

AN - SCOPUS:84906996719

VL - 106

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 8

M1 - dju165

ER -